knowledge -WSS

knowledge

author：knowledge 2025-08-11 07:59:05 - browse：371

What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.

For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Helping hospitals and community health centers plan for resilience

WSS

Microbiome research is starting to find links to chronic diseases

Second House panel advances two

What Congress can do to address the rural doctor shortage

CommonSpirit Health keeps growing, even as it loses money

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Wikipedia

knowledge

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Changes to biosimilar regulatory framework must prioritize patients

In age of alternative facts, a scholarly course on calling out crap

CDC advisers recommend seasonal use of Pfizer RSV shot

Virginia high school admissions case could be legal follow

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Medical records are filled with copy

FDA panel to weigh approval of NurOwn, controversial ALS drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech stock slump in 2023: awaiting the turnaround

focus

Solving academic medical centers' existential crisis

HIV vaccine remains elusive. Immunologists keep trying new ideas

Venture capitalist Bob Kocher on the state of digital health

Drug for rare kidney disease narrowly misses mark in clinical trial

HIV vaccine remains elusive. Immunologists keep trying new ideas

Emergency workers more likely to restrain Black patients: study

focus

knowledge

explore

Wikipedia